Budesonide + Glycopyrrolate + Formoterol: Over 90% of COPD patients report early relief

Hana Mullerova and colleagues uncovered exceptional findings on the effectiveness of Budesonide/Glycopyrrolate/Formoterol (BGF) in tackling COPD in real-world settings. Unlike traditional clinical trials, this investigation delved deep into the daily lives of patients, offering unprecedented insights that could improve COPD care.

The study published in the International Journal of Chronic Obstructive Pulmonary Disease, was performed using real-world data from the UK Optimum Patient Care Research Database, followed 285 COPD patients who initiated BGF therapy (≥2 prescriptions within 90 days). They were followed from the first prescription until 180 days, mortality, leaving the database or end of data on 24, October 2022.

Medicine success at 90 days and 180 days after the start of triple therapy, defined as no major cardiac or respiratory event and no frequency of pneumonia comprised of the primary outcomes.

Many of the patients faced acute airflow obstruction and exhibited signs of excessive short-acting β2-agonist usage (62.1%), recurrent oral corticosteroid prescriptions (33%), and frequent visits to general physicians (61.1%) before starting BGF treatment. However, the introduction of BGF led to remarkable improvements, with many patients transitioning from previous therapies. After just 90 days of treatment, an overwhelming 96.5% of patients experienced medication success, meaning they avoided severe cardiac or respiratory events. Interestingly, this success was sustained over 180 days for 91.8% of patients.